Francois C. Bidard
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer.
Journal: The oncologist
Published: January 22, 2026
Efficacy and toxicity of post-neoadjuvant trastuzumab emtansine in HER2-positive breast cancer patients treated at Institut Curie Hospitals.
Journal: Scientific reports
Published: March 25, 2025
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report.
Journal: Critical reviews in oncology/hematology
Published: January 29, 2025
Hyperprogressive Disease After Pembrolizumab Treatment in Advanced Epstein-Barr Virus-Associated Gastric Adenocarcinoma With ERBB2 Amplification.
Journal: JCO precision oncology
Published: January 07, 2022
AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME-Paris) and European School of Oncology (ESO - Milan).
Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology
Published: December 02, 2019
A covariate-specific time-dependent receiver operating characteristic curve for correlated survival data.
Journal: Statistics in medicine
Published: December 10, 2018
First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.
Journal: Anticancer research
Published: October 28, 2016
Diffusion-weighted MRI for uveal melanoma liver metastasis detection.
Journal: European radiology
Published: August 18, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026